Tuesday, August 12, 2025

Ebola

Ebola Virus Disease (EVD): A Comprehensive Overview

~Introduction

Ebola Virus Disease (EVD), commonly known as Ebola, is one of the deadliest viral infections known to humanity. Caused by the Ebola virus, this disease is characterized by severe fever, internal bleeding, and high mortality rates.

Since its discovery in 1976, Ebola has caused several major outbreaks, mainly in sub-Saharan Africa, with death rates sometimes exceeding 90%. Although outbreaks are typically limited geographically, the virus’s extreme virulence, potential for rapid spread, and lack of definitive treatment have made it a priority for global health preparedness.

~Historical Background

Discovery

The Ebola virus was first identified in 1976 during two simultaneous outbreaks:

Yambuku, Zaire (now the Democratic Republic of Congo) – near the Ebola River, from which the virus gets its name.
Nzara, Sudan – a similar outbreak occurred almost at the same time.

Both outbreaks caused hundreds of deaths, with mortality rates of 88% in Zaire and 53% in Sudan. Researchers soon identified a filovirus as the causative agent.

Notable Outbreaks

1995 (DR Congo): Over 300 cases, high fatality rate.
2000–2001 (Uganda): More than 400 cases.
2014–2016 (West Africa): The largest outbreak in history, affecting Guinea, Liberia, and Sierra Leone. Over 28,000 cases and 11,000 deaths.
2018–2020 (Eastern DR Congo): Complicated by conflict and instability.
2021–2022: Smaller outbreaks in Guinea and DR Congo.

~The Ebola Virus

Classification

Family: Filoviridae
Genus: Ebolavirus
Species:
1. Zaire ebolavirus (most lethal)
2. Sudan ebolavirus
3. Bundibugyo ebolavirus
4. Taï Forest ebolavirus
5. Reston ebolavirus (non-pathogenic to humans)

Structure

Ebola viruses are filamentous, enveloped, and contain single-stranded negative-sense RNA. The viral envelope has glycoproteins that bind to host cells, initiating infection.

Natural Reservoir

Fruit bats (particularly species from the Pteropodidae family) are believed to be the natural hosts. The virus spills over to humans through:

Handling infected wildlife (monkeys, chimpanzees, forest antelopes)
Direct contact with bat secretions or contaminated fruits

~Transmission

Animal-to-Human Transmission

Contact with blood, secretions, organs, or other bodily fluids of infected animals
Hunting, butchering, or consuming bushmeat

Human-to-Human Transmission

Direct contact with the blood or bodily fluids of infected individuals
Contact with contaminated surfaces and objects (needles, bedding, clothing)
Burial practices involving direct handling of bodies
Sexual transmission (virus can persist in semen for months after recovery)

Important: Ebola is not airborne like influenza or measles. It requires close contact with infectious material.

~Pathophysiology

Once inside the body, the virus targets multiple cell types, particularly:

Immune cells (monocytes, macrophages, dendritic cells)
Endothelial cells (lining blood vessels)

Key steps:

Viral entry: Glycoproteins bind to host receptors, facilitating viral entry via macropinocytosis.
Replication: The virus hijacks the host cell machinery to replicate.
Immune evasion: Ebola suppresses interferon production, blunting the immune response.
Cytokine storm: Excessive inflammatory signaling damages tissues.
Vascular leakage: Weakening of blood vessel walls leads to bleeding and shock.

~Symptoms

The incubation period ranges from 2 to 21 days (average 8–10 days). Ebola symptoms progress in stages:

Early Stage

Sudden onset of fever
Fatigue
Muscle and joint pain
Headache
Sore throat

Progressive Stage

Vomiting and diarrhea
Rash
Abdominal pain
Conjunctivitis (red eyes)

Severe Stage

Internal and external bleeding (nose, gums, puncture sites)
Impaired organ function
Shock
Multi-organ failure

Mortality rate: Varies by strain and outbreak, ranging from 25% to 90%.

~Diagnosis

Early symptoms resemble malaria, typhoid, or meningitis, making laboratory confirmation essential.

Laboratory Tests

RT-PCR: Detects viral RNA (gold standard for confirmation)
ELISA: Detects Ebola-specific antigens or antibodies
Virus isolation: Conducted only in biosafety level 4 labs
Post-mortem testing: For safe confirmation after death

~Treatment

There is no single universally approved antiviral cure, but recent developments have improved survival rates.

Supportive Care

Rehydration with oral or intravenous fluids
Maintaining oxygen status and blood pressure
Treating secondary infections
Pain and fever management

Specific Therapies

Monoclonal antibody treatments:
- Inmazeb (REGN-EB3)
- Ebanga (mAb114)
Experimental antivirals:
- Remdesivir (less effective than antibodies in trials)
Convalescent plasma: Limited success

Key point: Early supportive care significantly increases chances of survival.

~Prevention

For Individuals

Avoid contact with infected individuals or animals
Use personal protective equipment (PPE) when caring for patients
Practice safe burial procedures

For Communities

Rapid isolation of suspected cases
Contact tracing and monitoring for 21 days
Public health education on hygiene and safe practices

Vaccination

rVSV-ZEBOV (Ervebo): Highly effective against Zaire ebolavirus; used in outbreak response.
Johnson & Johnson vaccine: Two-dose regimen for longer-term protection in high-risk populations.

~Impact on Society

Health Systems

Ebola outbreaks strain fragile healthcare systems, diverting resources from other diseases.

Economic Consequences

Trade restrictions
Collapse of local markets
Declines in tourism and foreign investment

Social and Cultural Impact

Stigma against survivors
Disruption of traditional burial practices
Psychological trauma among survivors, families, and health workers

~Global Response

The 2014–2016 outbreak marked a turning point in international outbreak response.

Key Players

World Health Organization (WHO)
Centers for Disease Control and Prevention (CDC)
Médecins Sans Frontières (MSF)
Local ministries of health

Response Measures

Establishment of Ebola Treatment Units (ETUs)
Use of "ring vaccination" to immunize contacts
Deployment of rapid diagnostic tests
Strengthening community engagement

~Ebola vs. Other Viral Hemorrhagic Fevers

Feature	Ebola	Marburg	Lassa	Crimean-Congo HF
Causative Virus	Ebola virus	Marburg virus	Lassa virus	CCHF virus
Mortality Rate	25–90%	23–90%	1–15%	10–40%
Reservoir	Fruit bats	Fruit bats	Mastomys rats	Ticks, livestock
Vaccine	Yes (Zaire strain)	In development	None	None

~Lessons Learned

Early Detection Saves Lives – Delays in identifying outbreaks lead to exponential spread.
Community Trust is Crucial – Rumors and misinformation can hinder control efforts.
Global Preparedness – Stronger health systems and rapid-response teams are essential.
Investment in Research – Development of vaccines and therapeutics must continue.

~Current Status

Ebola remains a recurrent threat in Central and West Africa. Although vaccines and treatments exist, outbreaks still occur due to:

Limited healthcare access
Political instability
Close human-animal contact in rural areas

Ongoing research aims to:

Develop multi-strain vaccines
Improve rapid diagnostics
Strengthen community-based prevention

~Conclusion

Ebola Virus Disease is one of the most dangerous infectious diseases, with a history of devastating outbreaks. While scientific advances have significantly improved our ability to respond, Ebola’s capacity to cause high mortality, disrupt societies, and spread rapidly in under-resourced regions means it will remain a public health priority.

The lessons from Ebola have reshaped outbreak response strategies worldwide, highlighting the importance of early detection, community engagement, strong health systems, and international solidarity in facing infectious threats.